R&D News | pharmaphorum

News

Gritstone bio trumpets first data for 'multivariant' COVID j...

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinica

News

Biogen looks beyond Spinraza in SMA with Ionis deal

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer's spesolimab data raises hope for serious skin di...

Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim's spesolimab has shown encouraging efficacy in a phase 2 trial in generalised pustular psoriasis (GPP), a rar

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Novartis adds gene therapy for blindness with Gyroscope buy

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect.

News

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking

News

Ipsen places €480m bet on Genfit's liver drug elafibranor

Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and

Gritstone bio trumpets first data for 'multivariant' COVID j...

Biogen looks beyond Spinraza in SMA with Ionis deal

Boehringer's spesolimab data raises hope for serious skin di...

Novartis adds gene therapy for blindness with Gyroscope buy

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Ipsen places €480m bet on Genfit's liver drug elafibranor

Danco fights back after US court curbs abortion pill access

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks